Tricuspid Valve Disease clinical trials at UCSF
2 research studies open to eligible people
Tricuspid valve disease is a condition that affects the tricuspid valve in the heart. UCSF is conducting clinical trials to evaluate new treatments for tricuspid valve disease. One trial is testing the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system. Another trial is investigating the Edwards PASCAL Transcatheter Repair System for patients with severe tricuspid regurgitation.
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
open to eligible people ages 18 years and up
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
San Francisco, California and other locations
TRISCEND II Pivotal Trial
open to eligible people ages 18 years and up
Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system
San Francisco, California and other locations
Our lead scientists for Tricuspid Valve Disease research studies include Sammy Elmariah, MD.
Last updated: